Lupus & antiphospholipid syndrome
Monoclonal gammopathy in systemic lupus erythematosus is associated with distinctive clinical course, malignancy and mortality rate: a single-centre retrospective cohort study
Authors' conclusion
Our study emphasises heightened malignancy and mortality rates in SLE+MG cases.
Study context
- Population
- Patients with SLE (1997 American College of Rheumatology (ACR), 2019 EULAR/ACR and/or 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria) managed at two tertiary care departments of the University Hospital, Krakow, Poland, January 2012–November 2019
- Participants
- 1,039 patients
- Exposure
- SLE with monoclonal gammopathy (MG) vs SLE without MG
- Outcome
- Prevalence, malignant transformation risk, clinical correlates and prognostic impact of MG in SLE
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Malignancy · median follow-up 11 years
P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Death | 2.99 (1.26–7.06) | P < 0.05 | |
| 0.10.31310Hazard ratio (log scale) |
Survival time from SLE diagnosis to death
Range SLE+MG 0-41 · Non-MG SLE controls 0-62
Age at SLE diagnosis
P < 0.01
Treated with CYC
P < 0.01
Treated with RTX
P < 0.01
- Lymphopenia, anaemia, haemolysis, serous effusions and ILD
- all p<0.05
- Death: The effect was non-independent on antimalarial medication use
Lymphopenia, anaemia, haemolysis, serous effusions and ILD
- Higher rates in SLE+MG
Time from SLE diagnosis to MG detection
- Most MG cases detected within a year after SLE diagnosis (Q25, Q75: 0, 12 years)
Original publication
Monoclonal gammopathy in systemic lupus erythematosus is associated with distinctive clinical course, malignancy and mortality rate: a single-centre retrospective cohort study. Lupus Sci Med. Published 30 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →